Abstract

The UK regulatory environment continues to evolve as the Medicines and Healthcare products Regulatory Agency (MHRA) strengthens its position as a sovereign regulator and refines the balance between national procedures and the International Recognition Procedure (IRP). For marketing authorisation holders (MAHs) managing grandfathered centrally authorised products (CAPs), this shift presents both challenges and new strategic opportunities.

This article examines four real-world case studies where UK lifecycle pathways diverged from EU timelines, including parallel national and IRP submissions, national safety variations progressing ahead of EU worksharing submissions, and UK upgrades of EU-classified Type IB chemistry, manufacturing and controls (CMC) changes. Across these examples, proactive engagement with the MHRA, early strategic planning and careful assessment of business priorities were crucial in achieving timely product information updates and ensuring uninterrupted patient access.

Emerging trends suggest that divergence between the UK and the EU is increasing but stabilising, with clear signals of MHRA agility and willingness to provide pragmatic, case-specific guidance. The article outlines lessons learned, practical recommendations for MAHs, and strategic considerations for using IRP and national pathways effectively in the coming years to ensure adaptive and collaborative regulatory approaches in a post-Brexit landscape.